Associated Papers
Integrating evidence from protein domains to identify cancer driver mutations.
Ostroverkhova D et al.
Protein Science : a Publication of the Protein Society, 2026
Comparison between a Luminex-based multiplex kit with a sequence-specific oligonucleotide probe and next-generation sequencing for the detection of POLE oncogenic mutations in endometrial cancer.
Kato MK et al.
Virchows Archiv : an International Journal of Pathology, 2025
Comprehensive Analysis of Human Colorectal Cancers Harboring Polymerase Epsilon Mutations.
Gibson LM et al.
International Journal of Molecular Sciences, 2025
Functions, interactions and prognostic role of POLE: a bioinformatics analysis.
Carvajal-Veloza J et al.
Journal of Gynecologic Oncology, 2025
POLE-mutated endometrial cancer: new perspectives on the horizon?
Fanale D et al.
Frontiers in Oncology, 2025
Germline mutations of homologous recombination genes and clinical outcomes in pancreatic cancer: a multicenter study in Taiwan.
Cheng SM et al.
Journal of Biomedical Science, 2024
DNA polymerase ε and δ variants drive mutagenesis in polypurine tracts in human tumors.
Ostroverkhova D et al.
Cell Reports, 2024
The game-changing impact of POLE mutations in oncology-a review from a gynecologic oncology perspective.
Kögl J et al.
Frontiers in Oncology, 2024
Recommendations for the classification of germline variants in the exonuclease domain of POLE and POLD1.
Mur P et al.
Genome Medicine, 2023
In-silico analysis of TCGA data showing multiple POLE-like favourable subgroups overlapping with TP53 mutated endometrial cancer: Implications for clinical practice in low and middle-income countries.
Das Ghosh D et al.
Gynecologic Oncology Reports, 2023
Molecular profiling of a real-world breast cancer cohort with genetically inferred ancestries reveals actionable tumor biology differences between European ancestry and African ancestry patient populations.
Miyashita M et al.
Breast Cancer Research : Bcr, 2023
A novel somatic mutation in POLE exonuclease domain associated with ultra-mutational signature and MMR deficiency in endometrial cancer: a case report.
Cui J et al.
Diagnostic Pathology, 2023
POLE/POLD1 mutation in non-exonuclease domain matters for predicting efficacy of immune-checkpoint-inhibitor therapy.
Chen YX et al.
Clinical and Translational Medicine, 2021
Mismatch repair status influences response to fertility-sparing treatment of endometrial cancer.
Chung YS et al.
American Journal of Obstetrics and Gynecology, 2021
Interpretation of somatic POLE mutations in endometrial carcinoma.
León-Castillo A et al.
The Journal of Pathology, 2020
POLE Mutation Characteristics in a Chinese Cohort with Endometrial Carcinoma.
Li Y et al.
Oncotargets and Therapy, 2020
Tumor mutational signatures in sebaceous skin lesions from individuals with Lynch syndrome.
Georgeson P et al.
Molecular Genetics & Genomic Medicine, 2019
Targeted Molecular and Immunohistochemical Analyses of Endometrial Clear Cell Carcinoma Show that POLE Mutations and DNA Mismatch Repair Protein Deficiencies Are Uncommon.
Baniak N et al.
The American Journal of Surgical Pathology, 2019
Deep sequencing of uveal melanoma identifies a recurrent mutation in PLCB4.
Johansson P et al.
Oncotarget, 2016
Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations.
Hussein YR et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 2015
POLE exonuclease domain mutation predicts long progression-free survival in grade 3 endometrioid carcinoma of the endometrium.
Meng B et al.
Gynecologic Oncology, 2014